Ultragenyx Pharmaceutical Inc. (LON: 0LIF)

Market Cap	3.09B
Revenue (ttm)	390.02M
Net Income (ttm)	-417.06M
Shares Out	n/a
EPS (ttm)	-4.80
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,230
Average Volume	386
Open	41.35
Previous Close	40.92
Day's Range	41.15 - 42.26
52-Week Range	29.59 - 47.50
Beta	n/a
RSI	44.73
Earnings Date	Feb 10, 2025

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and ad...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Employees: 1,276
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0LIF

Financial Performance

In 2023, Ultragenyx Pharmaceutical's revenue was $434.25 million, an increase of 19.52% compared to the previous year's $363.33 million. Losses were -$606.64 million, -14.25% less than in 2022.

Financial numbers in USD